Optimization of the Development of Old and New EGFR and MAP Kinase Inhibitors for Colorectal Cancer
- 78 Downloads
The epidermal growth factor receptor (EGFR) and its downstream signaling pathways are crucially important in the biology of colorectal cancer (CRC). In the past few years, EGFR kinase and its major downstream effector, the RAS/RAF/MAPK/ERK pathway, have been attractive targets for development of new therapy for treatment of metastatic CRC (mCRC). Cetuximab and panitumumab, two monoclonal antibodies (mAbs) against the EGFR, are the first targeted agents approved as personalized medicine for treatment of mCRC. Recently, inhibition of MEK1/2 has been seen as a promising approach for blocking MAPK-mediated proliferation signals. Several compounds with highly selective inhibitory effects on MEK1/2 have been developed and have entered clinical trials. New therapeutic agents have also been used to optimize personalized treatment of mCRC. In this context we discuss recent advances in research on EGFR and MAPK inhibitors.
KeywordsEGFR inhibitors MAPK pathway Colorectal cancer Nanotechnology Cetuximab Panitumumab Selumetinib Pimasertib
Compliance with Ethics Guidelines
Conflict of Interest
Erika Martinelli, Stefania Napolitano, Davide Ciardiello, Fortunato Ciardiello, and Teresa Troiani declare that they have no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 11.•Douillard JY, Siena S, Cassidy J, et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol. 2010;28:4697–705. The authors emphasize the importance of KRAS testing for patients with mCRC.PubMedCrossRefGoogle Scholar
- 26.•Tveit KM, Guren T, Glimelius B, et al. Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study. J Clin Oncol. 2012;30:1755–62. In this trial the authors showed that cetuximab did not add significant benefit to the FLOX regimen for first-line treatment of mCRC.PubMedCrossRefGoogle Scholar
- 30.Van Cutsem E Lang I, Folprecht G, et al. Cetuximab plus FOLFIRI in the treatment of metastatic colorectal cancer (mCRC): The influence of KRAS and BRAF biomarkers on outcome: Updated data from the CRYSTAL trial. Presented at the 2010 Gastrointestinal Cancers Symposium, Jan 22-24, Orlando, FL. Abstract 281.Google Scholar
- 31.Kohne C, Rogier P, Stroh C. Cetuximab with chemotherapy (CT) as first-line treatment for metastatic colorectal cancer (mCRC): A meta-analysis of the CRYSTAL and OPUS studies according to KRAS and BRAF mutation status. Presented at the 2010 Gastrointestinal Cancers Symposium, Jan 22-24, Orlando, FL. Abstract 406.Google Scholar
- 32.••Douillard JY, Oliner KS, Siena S, et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med. 2013;369:1023–34. In this trial the authors emphasize the importance of better selection of patients who might benefit from anti-EGFR moAbs by considering other RAS mutations.PubMedCrossRefGoogle Scholar
- 33.••Stintzing S, Jung A, Rossius L, et al. Analysis of KRAS/NRAS and BRAF mutations in FIRE-3: A randomized phase III study of FOLFIRI plus cetuximab or bevacizumab as first-line treatment for wild-type (WT) KRAS (exon 2) metastatic colorectal cancer (mCRC) patients. ESMO 2013, Amsterdam, The Netherlands: abstract LBA 17. This trial emphasizes the importance of RAS analysis and is the first randomised multicenter study to directly compare two biological agents that are active in mCRC. Google Scholar
- 34.••Ciardiello F, Normanno N, Maiello E, et al. Molecular profiling of the CAPRI GOIM trial in KRAS wild type (wt) metastatic colorectal cancer (mCRC) patients (pts): Cetuximab + FOLFIRI followed by FOLFOX4 ± cetuximab. ESMO 2013. Amsterdam, The Netherlands: abstract LBA 31. The authors report high intra and inter-tumor heterogeneity, indicating that several mutations can coexist in the same cancer cell, and, by considering RAS mutations, identify a subgroup of patients most likely to benefit from FOLFIRI plus cetuximab in first-line treatment. Google Scholar
- 36.Peeters M, Price T, Hotko Y, et al. Randomized phase III study (20050181) of panitumumab with FOLFIRI compared to FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer (mCRC). Eur J Cancer. 2009;7:9.Google Scholar
- 37.European Medicines Agency: Committee for Medicinal Products for Human Use. May 2008 plenary meeting monthly report. http://www.emea.europa.eu/pdfs/human/press/pr/27923508en.pdf.
- 38.Genome Web Daily News. FDA adds KRAS testing info to Vectibix, Erbitux Labels (Press Release, Genome Web News). http://www.genomeweb.com/dxpgx/fda-adds-kras-testing-info-vectibix-erbituxlabels.
- 44.Tabernero et al. An Open-label, Multi-center Phase I Dose Escalation Study to Investigate the Safety and Tolerability of Multiple Doses of Sym004 in Patients With Advanced Solid Tumors. ClinicalTrials.gov Identifier: NCT01117428.Google Scholar
- 47.Paz Ares L, Gomez Roca C, Delord JP, et al. Phase I pharmacokinetic and pharmacodynamic dose-escalation study of RG7160 (GA201), the first glycoengineered monoclonal antibody against the epidermal growth factor receptor (EGFR) in patients with advanced solid tumors. J Clin Oncol. 2011;29:3783–90.PubMedCrossRefGoogle Scholar
- 48.Cervantes-Ruiperez A, Markman B, Siena S. et al. The GAIN-C study (BP25438): Randomized phase II trial of RG7160 (GA201) plus FOLFIRI, compared to cetuximab plus FOLFIRI or FOLFIRI alone in second-line KRAS wild type (WT) or mutant metastatic colorectal cancer (mCRC). ASCO Annual Meeting. 2012. J Clin Oncol 30, 2012abstr: TPS3637A).Google Scholar
- 54.Sebolt-Leopold JS. MEK inhibitors: a therapeutic approach to targeting the Ras-MAP kinase pathway in tumors. Curr Pharm Des. 2004; 1907–14.Google Scholar
- 55.Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417949–54.Google Scholar
- 60.Davies BR, Logie A, McKay JS, et al. AZD6244 (ARRY- 142886), a potent inhibitor of mitogen-activated protein kinase/ extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models. Mol Cancer Ther. 2007;6:2209–19.PubMedCrossRefGoogle Scholar
- 63.Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small- molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26:2139–46.PubMedCentralPubMedCrossRefGoogle Scholar
- 65.Hainsworth JD, Cebotaru CL, Kanarev V, et al. A phase II, open-label, randomized study to assess the efficacy and safety of AZD6244 (ARRY-142886) versus pemetrexed in patients with non-small cell lung cancer who have failed one or two prior chemotherapeutic regimens. J Thorac Oncol. 2010;5:1630–6.PubMedCrossRefGoogle Scholar
- 66.Bodoky G, Timcheva C, Spigel DR, et al. A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy. Investig New Drugs. 2012;30:1216–23.CrossRefGoogle Scholar
- 67.Bennouna J, Lang I, Valladares-Ayerbes M, et al. A Phase II, open-label, randomized study to assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimens. Investig New Drugs. 2011;29:1021–8.CrossRefGoogle Scholar
- 69.SchelmanW et al. Selumetinib and Cetuximab in Treating Patients With Refractory Solid Tumors. ClinicalTrials.gov identifier: NCT01217450.Google Scholar
- 70.Azad N et al. Selumetinib and Cixutumumab in Treating Patients With Advanced Solid Malignancies. ClinicalTrials.gov Identifier: NCT01061749.Google Scholar
- 74.Infante JR, Fecher LA, Nallapareddy S, et al. Safety and efficacy results from the first-in-human study of the oral MEK 1/2 inhibitor GSK1120212. J Clin Oncol. 2010;28 abstr:2503.Google Scholar
- 77.Wuthrick E et al. Trametinib, Fluorouracil, and Radiation Therapy Before Surgery in Treating Patients With Stage II-III Rectal Cancer.ClinicalTrials.gov Identifier: NCT0174064Google Scholar
- 78.Houede N, Faivre SJ, Awada A, et al. Safety and evidence of activity of MSC1936369, an oral MEK1/2 inhibitor, in patients with advanced malignancies. J Clin Oncol. 2011; 2915s, abstr 3019.Google Scholar
- 79.Macarulla T, Cervantes A, Roselló S, et al. Phase i/ii study of folfiri plus the mek1/2 inhibitor pimasertib (msc1936369b) as second-line treatment for kras mutated metastatic colorectal cancer. Ann Oncol. 2012;23 suppl 4:iv19–30.Google Scholar
- 80.Sidhu SS, Egile C, Malfilatre M et al. Anti-tumor activity of pimasertib in combination with SAR245409 or SAR245408 in human primary colorectal cancer xenograft models bearing PI3K/KRas and KRas mutations. Cancer Research. 2013; Volume 73, Issue 8, Supplement 1 doi: 10.1158/1538-7445.AM2013-4638, AACR 104th Annual Meeting 2013; Apr 6-10; Washington, DC. Abstract 4638Google Scholar
- 81.Martinelli E, Troiani T, D’Aiuto E. Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells. Int J Cancer. 2013;133:2089–101.PubMedCrossRefGoogle Scholar
- 83.Little AS, Balmanno K, Sale MJ, et al. Amplification of the driving oncogene, KRAS or BRAF, underpins acquired resistance to MEK1/2 inhibitors in Colorectal Cancer cells. Sci Signal. 2011;4:170.Google Scholar
- 86.•De Roock W, De Vriendt V, Nomanno N, et al. KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer. Lancet Oncol. 2011;12:594–603. The authors show that other activating RAS mutations predict poorer outcome for mCRC patients treated with both cetuximab and panitumumab.PubMedCrossRefGoogle Scholar